NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a report published on Thursday morning. The firm issued a hold rating on the stock.

Separately, Ascendiant Capital Markets reduced their price target on shares of NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating for the company in a research note on Monday, November 11th.

NovaBay Pharmaceuticals Price Performance

NovaBay Pharmaceuticals stock opened at $0.53 on Thursday. NovaBay Pharmaceuticals has a one year low of $0.36 and a one year high of $9.10. The business’s fifty day moving average is $0.63 and its 200 day moving average is $1.05. The stock has a market capitalization of $2.60 million, a PE ratio of -0.01 and a beta of 0.69.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.